These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39080523)

  • 1. Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method.
    Kimura R; Nomura S; Nagashima K; Sato Y
    BMC Med Res Methodol; 2024 Jul; 24(1):166. PubMed ID: 39080523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simulation study for comparing testing statistics in response-adaptive randomization.
    Gu X; Lee JJ
    BMC Med Res Methodol; 2010 Jun; 10():48. PubMed ID: 20525382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjusting for multiple prognostic factors in the analysis of randomised trials.
    Kahan BC; Morris TP
    BMC Med Res Methodol; 2013 Jul; 13():99. PubMed ID: 23898993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
    Yang S
    Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence balance minimisation: minimising with unequal treatment allocations.
    Madurasinghe VW
    Trials; 2017 May; 18(1):207. PubMed ID: 28468678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improper analysis of trials randomised using stratified blocks or minimisation.
    Kahan BC; Morris TP
    Stat Med; 2012 Feb; 31(4):328-40. PubMed ID: 22139891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consideration of stratification in confirmatory trials with time-to-event endpoint.
    Wang Y; Zhou X; Guo Z; Fang X; Liu F; Shen L
    Contemp Clin Trials; 2024 Jun; 141():107434. PubMed ID: 38215875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the relationship between predictability and imbalance in minimisation: a simulation study.
    McPherson GC; Campbell MK; Elbourne DR
    Trials; 2013 Mar; 14():86. PubMed ID: 23537389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inference following designs which adjust for imbalances in prognostic factors.
    Barbáchano Y; Coad DS
    Clin Trials; 2013 Aug; 10(4):540-51. PubMed ID: 23832671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A win ratio approach for comparing crossing survival curves in clinical trials.
    Zheng S; Wang D; Qiu J; Chen T; Gamalo M
    J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of factorial survival experiments.
    Slud EV
    Biometrics; 1994 Mar; 50(1):25-38. PubMed ID: 8086609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimisation for the design of parallel cluster-randomised trials: An evaluation of balance in cluster-level covariates and numbers of clusters allocated to each arm.
    Martin J; Middleton L; Hemming K
    Clin Trials; 2023 Apr; 20(2):111-120. PubMed ID: 36661245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.